FDA Says Single-dose Vaccine Shot From J&J Prevents Severe C
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Johnson & Johnson's single-dose vaccine protects against Covid-19, according to an analysis by U.S. regulators that sets the stage for a final decision on a new and easier-to-use shot to help tame the pandemic. FDA scientists confirmed that overall the vaccine is about 66% effective at preventing moderate to severe Covid-19.

J&J tested its single-dose option in 44,000 people in the U.S., Latin America, and South Africa. Different mutated versions of the virus are circulating in different countries, and the FDA analysis cautioned that it's not clear how well the vaccine works against each variant. But J&J previously announced the vaccine worked better in the U.S. -- 72% effective against moderate to severe Covid-19, compared with 66% in Latin America and 57% in South Africa.

J&J was on track to become the world's first one-dose option until Mexico announced it would use a one-dose version. That vaccine is made with similar technology as J&J's but initially was developed as a two-dose option. The J&J shot can last three months in the refrigerator, making it easier to handle.

Source:
https://health.economictimes.indiatimes.com/news/pharma/fda-says-jj-single-dose-shot-prevents-covid-final-decision-soon/81201341
Dr. T●●●●z H●●●●●●i and 3 others like this1 share
Like
Comment
Share